Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity
Taojun Ye,
Anqi Lin,
Zhengang Qiu,
Shulu Hu,
Chaozheng Zhou,
Zaoqu Liu,
Quan Cheng,
Jian Zhang,
Peng Luo
Affiliations
Taojun Ye
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; The First Clinical Medical School, Southern Medical University, Guangzhou, Guangdong, China
Anqi Lin
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; The First Clinical Medical School, Southern Medical University, Guangzhou, Guangdong, China
Zhengang Qiu
The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
Shulu Hu
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; The First Clinical Medical School, Southern Medical University, Guangzhou, Guangdong, China
Chaozheng Zhou
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; The First Clinical Medical School, Southern Medical University, Guangzhou, Guangdong, China
Zaoqu Liu
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Quan Cheng
Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China; Corresponding author
Jian Zhang
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; The First Clinical Medical School, Southern Medical University, Guangzhou, Guangdong, China; Corresponding author
Peng Luo
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; The First Clinical Medical School, Southern Medical University, Guangzhou, Guangdong, China; Corresponding author
Summary: There is an urgent need for markers to predict the efficacy of different chemotherapy drugs. Herein, we examined whether microsatellite instability (MSI) status can predict tumor multidrug sensitivity and explored the underlying mechanisms. We downloaded data from several public databases. Drug sensitivity was compared between the high microsatellite instability (MSI-H) and microsatellite-stable/low microsatellite instability (MSS/MSI-L) groups. In addition, we performed pathway enrichment analysis and cellular chemosensitivity assays to explore the mechanisms by which MSI status may affect drug sensitivity and assessed the differences between drug-treated and control cell lines. We found that multiple MSI-H tumors were more sensitive to a variety of chemotherapy drugs than MSS/MSI-L tumors, and especially for CRC, chemosensitivity is enhanced through the downregulation of DDR pathways such as NHEJ. Additional DNA damage caused by chemotherapeutic drugs results in further downregulation of DDR pathways and enhances drug sensitivity, forming a cycle of increasing drug sensitivity.
